[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @Giulio01839130 Giulio Giulio posts on X about $pvla, $1b, $nvda, default risk the most. They currently have XXX followers and XX posts still getting attention that total XXX engagements in the last XX hours. ### Engagements: XXX [#](/creator/twitter::1082737213673226242/interactions)  - X Week XXX -XX% - X Month XXXXX +1,762% - X Months XXXXX -XX% - X Year XXXXXX -XX% ### Mentions: X [#](/creator/twitter::1082737213673226242/posts_active)  ### Followers: XXX [#](/creator/twitter::1082737213673226242/followers)  - X Week XXX +2.30% - X Month XXX +9.10% - X Months XXX +9.10% - X Year XXX +5.90% ### CreatorRank: XXXXXXXXX [#](/creator/twitter::1082737213673226242/influencer_rank)  ### Social Influence **Social category influence** [finance](/list/finance) XXXXX% [stocks](/list/stocks) XXXX% [technology brands](/list/technology-brands) XXXX% **Social topic influence** [$pvla](/topic/$pvla) 7.41%, [$1b](/topic/$1b) 7.41%, [$nvda](/topic/$nvda) #3883, [default risk](/topic/default-risk) #233, [products](/topic/products) 3.7%, [ai](/topic/ai) 3.7%, [target](/topic/target) 3.7%, [stocks](/topic/stocks) 3.7%, [liquidity](/topic/liquidity) 3.7%, [red](/topic/red) XXX% **Top assets mentioned** [NVIDIA Corp. (NVDA)](/topic/$nvda) ### Top Social Posts Top posts by engagements in the last XX hours "1/ $PVLA is one of the clearest market mispricings in small-cap biotech this year. The stock trades at a $1B valuation despite generating $X revenue having no approved products and facing severe financial risk. A valuation built on storytelling not fundamentals" [X Link](https://x.com/Giulio01839130/status/1998492225873846681) 2025-12-09T20:37Z XXX followers, XXX engagements "Everyone is calling $NVDA expensive. My DCF says the stock is mispriced by 75%. The real target XXXXXX. This is NOT priced in. #stocks #AI #tech" [X Link](https://x.com/Giulio01839130/status/2000496050654576743) 2025-12-15T09:20Z XXX followers, XX engagements "3/ Cash burn and liquidity risk are flashing red. Based on recent filings PVLAs cash runway is limited and the company faces a 40%+ implied refinancing yield if it attempted to raise debt. Thats distressed-level financing not a growth profile" [X Link](https://x.com/Giulio01839130/status/1998492792255824184) 2025-12-09T20:39Z XXX followers, XX engagements "4/ Default probability models place PVLA at 6080% 12-month default risk and 90%+ over a 3-year horizon unless fresh capital is raised. This is inconsistent with a $1B equity valuation" [X Link](https://x.com/Giulio01839130/status/1998492917208428970) 2025-12-09T20:40Z XXX followers, XX engagements "6/ The pipeline is early. Phase X data for Microcystic LM is years away from commercialization. Other programs (cVM Gorlin DSAP) are Phase X or preclinical with no near-term revenue catalysts. Even in success scenarios orphan drug launches build gradually. Yet PVLAs valuation already prices in years of flawless execution and a high probability of approval something the data does not support" [X Link](https://x.com/Giulio01839130/status/1998493194082775246) 2025-12-09T20:41Z XXX followers, XX engagements "8/ $PVLA This is a company with: No revenue No approved drugs High clinical risk High dilution risk High default risk A financing curve equivalent to distressed credit But trading like a high-certainty growth story" [X Link](https://x.com/Giulio01839130/status/1998493335099424774) 2025-12-09T20:41Z XXX followers, XXX engagements "At XXXXXX $NVDA trades at a huge discount to intrinsic value. Market is ignoring exponential FCF compounding and AI's secular momentum. Consensus sees risk. The numbers show opportunity" [X Link](https://x.com/Giulio01839130/status/2000496056384012321) 2025-12-15T09:20Z XXX followers, XX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@Giulio01839130 Giulio
Giulio posts on X about $pvla, $1b, $nvda, default risk the most. They currently have XXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.
Engagements: XXX #
- X Week XXX -XX%
- X Month XXXXX +1,762%
- X Months XXXXX -XX%
- X Year XXXXXX -XX%
Mentions: X #
Followers: XXX #
- X Week XXX +2.30%
- X Month XXX +9.10%
- X Months XXX +9.10%
- X Year XXX +5.90%
CreatorRank: XXXXXXXXX #
Social Influence
Social category influence finance XXXXX% stocks XXXX% technology brands XXXX%
Social topic influence $pvla 7.41%, $1b 7.41%, $nvda #3883, default risk #233, products 3.7%, ai 3.7%, target 3.7%, stocks 3.7%, liquidity 3.7%, red XXX%
Top assets mentioned NVIDIA Corp. (NVDA)
Top Social Posts
Top posts by engagements in the last XX hours
"1/ $PVLA is one of the clearest market mispricings in small-cap biotech this year. The stock trades at a $1B valuation despite generating $X revenue having no approved products and facing severe financial risk. A valuation built on storytelling not fundamentals"
X Link 2025-12-09T20:37Z XXX followers, XXX engagements
"Everyone is calling $NVDA expensive. My DCF says the stock is mispriced by 75%. The real target XXXXXX. This is NOT priced in. #stocks #AI #tech"
X Link 2025-12-15T09:20Z XXX followers, XX engagements
"3/ Cash burn and liquidity risk are flashing red. Based on recent filings PVLAs cash runway is limited and the company faces a 40%+ implied refinancing yield if it attempted to raise debt. Thats distressed-level financing not a growth profile"
X Link 2025-12-09T20:39Z XXX followers, XX engagements
"4/ Default probability models place PVLA at 6080% 12-month default risk and 90%+ over a 3-year horizon unless fresh capital is raised. This is inconsistent with a $1B equity valuation"
X Link 2025-12-09T20:40Z XXX followers, XX engagements
"6/ The pipeline is early. Phase X data for Microcystic LM is years away from commercialization. Other programs (cVM Gorlin DSAP) are Phase X or preclinical with no near-term revenue catalysts. Even in success scenarios orphan drug launches build gradually. Yet PVLAs valuation already prices in years of flawless execution and a high probability of approval something the data does not support"
X Link 2025-12-09T20:41Z XXX followers, XX engagements
"8/ $PVLA This is a company with: No revenue No approved drugs High clinical risk High dilution risk High default risk A financing curve equivalent to distressed credit But trading like a high-certainty growth story"
X Link 2025-12-09T20:41Z XXX followers, XXX engagements
"At XXXXXX $NVDA trades at a huge discount to intrinsic value. Market is ignoring exponential FCF compounding and AI's secular momentum. Consensus sees risk. The numbers show opportunity"
X Link 2025-12-15T09:20Z XXX followers, XX engagements